TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · Real-Time Price · USD
53.22
+1.72 (3.34%)
At close: Jun 18, 2026, 4:00 PM EDT
52.50
-0.72 (-1.35%)
After-hours: Jun 18, 2026, 7:57 PM EDT

TG Therapeutics Stock Forecast

Stock Price Forecast

According to 9 analysts polled by S&P Global, TG Therapeutics stock has a consensus rating of "Buy" and an average price target of $48. The average 1-year stock price forecast is 9.81% lower than the current stock price, while the lowest is $17 (-68.06%) and the highest is $70 (+31.53%).

Price Target: $48 (-9.81%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$17$48$50$70
Change-68.06%-9.81%-6.05%+31.53%

Analyst Ratings

The average analyst rating for TG Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy666666
Buy111111
Hold111111
Sell111111
Strong Sell000000
Total999999

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
H.C. Wainwright
H.C. Wainwright
Buy
Maintains
$70
BuyMaintains$70+31.53%Jun 9, 2026
Bank of America Securities
Bank of America Securities
Sell
Maintains
$17
SellMaintains$17-68.06%Jun 4, 2026
Unknown Analyst
B. Riley Securities
No rating
B. Riley Securities
Buy
Reiterates
$55
BuyReiterates$55+3.34%Jun 4, 2026
Goldman Sachs
Goldman Sachs
Hold
Maintains
$41
HoldMaintains$41-22.96%Jun 4, 2026
J.P. Morgan
J.P. Morgan
Buy
Reiterates
n/a
BuyReiteratesn/an/aMay 27, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
941.11M
from 616.29M
Increased by 52.71%
Revenue Next Year
1.24B
from 941.11M
Increased by 31.74%
EPS This Year
1.54
from 2.77
Decreased by -44.58%
EPS Next Year
2.87
from 1.54
Increased by 87.09%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
6.69M2.79M233.66M329.00M616.29M941.11M
Revenue Growth
4,300.66%-58.36%8,290.02%40.80%87.32%52.71%
Gross Profit
5.90M2.52M219.53M290.52M515.57M803.71M
Gross Margin
88.19%90.48%93.95%88.30%83.66%85.40%
Operating Income
-344.77M-218.32M20.63M41.93M123.32M267.26M
Net Income
-348.10M-223.81M12.67M23.38M447.18M216.77M
EPS
----2.771.54
EPS Growth
----1,746.67%-44.58%
Forward PE
---45.2120.2934.67
Free Cash Flow
-166.60M-97.44M-47.55M-62.02M-43.98M303.00M
No. Analysts
-----8
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High966.5M
Avg941.1M
Low923.0M

Revenue Growth

Revenue Growth202620272028
High
56.8%
Avg
52.7%
Low
49.8%

EPS Forecast

EPS202620272028
High1.67
Avg1.54
Low1.30

EPS Growth

EPS Growth202620272028
High
-39.7%
Avg
-44.6%
Low
-53.1%